ES2185584T3 - Procedimiento para estabilizar preparaciones de polivinilpirrolidona. - Google Patents

Procedimiento para estabilizar preparaciones de polivinilpirrolidona.

Info

Publication number
ES2185584T3
ES2185584T3 ES00917004T ES00917004T ES2185584T3 ES 2185584 T3 ES2185584 T3 ES 2185584T3 ES 00917004 T ES00917004 T ES 00917004T ES 00917004 T ES00917004 T ES 00917004T ES 2185584 T3 ES2185584 T3 ES 2185584T3
Authority
ES
Spain
Prior art keywords
polivinylpirrolidone
procedure
preparations
stabilizing preparations
small amounts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00917004T
Other languages
English (en)
Inventor
Volker Buhler
Ulrich Filges
Tanja Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Application granted granted Critical
Publication of ES2185584T3 publication Critical patent/ES2185584T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/02—Elements
    • C08K3/08—Metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/02—Elements
    • C08K3/08—Metals
    • C08K2003/0843—Cobalt
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/02—Elements
    • C08K3/08—Metals
    • C08K2003/085—Copper
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/02—Elements
    • C08K3/08—Metals
    • C08K2003/0893—Zinc

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Procedimiento para el estabilizado de preparaciones pulverulentas y adecuadas como agentes auxiliares para la formulación de medicamentos, que contienen polivinilpirrolidona soluble o insoluble o copolímeros de polivinilpirrolidona o que consisten en ellos, caracterizado porque se agregan a las soluciones acuosas de los polímeros muy pequeñas cantidades de metales pesados, que son fisiológicamente compatibles en las cantidades aplicadas o enzimas, que disocian peróxidos, en muy pequeñas cantidades después de la polimerización y se transforma el polímero mediante secado en la forma pulverulenta.
ES00917004T 1999-04-06 2000-03-28 Procedimiento para estabilizar preparaciones de polivinilpirrolidona. Expired - Lifetime ES2185584T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19915420A DE19915420A1 (de) 1999-04-06 1999-04-06 Stabilisierte Polyvinylpyrrolidon-Zubereitungen

Publications (1)

Publication Number Publication Date
ES2185584T3 true ES2185584T3 (es) 2003-05-01

Family

ID=7903617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00917004T Expired - Lifetime ES2185584T3 (es) 1999-04-06 2000-03-28 Procedimiento para estabilizar preparaciones de polivinilpirrolidona.

Country Status (10)

Country Link
US (1) US6592900B1 (es)
EP (1) EP1083884B1 (es)
JP (1) JP2002541091A (es)
CN (1) CN1174743C (es)
AT (1) ATE226066T1 (es)
DE (2) DE19915420A1 (es)
DK (1) DK1083884T3 (es)
ES (1) ES2185584T3 (es)
PT (1) PT1083884E (es)
WO (1) WO2000059478A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4573998B2 (ja) * 2000-11-17 2010-11-04 株式会社日本触媒 ビニルピロリドン系重合体粉体の製造方法
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
WO2005072079A2 (en) 2003-09-26 2005-08-11 Alza Coporation Drug coating providing high drug loading and methods for providing the same
CA2540056C (en) * 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
DE102005005974A1 (de) 2005-02-09 2006-08-10 Basf Ag Verfahren zur Stabilisierung von Polyvinylpyrrolidonen
DE102005018465A1 (de) * 2005-04-20 2006-11-02 Basf Ag Bindemittel für Tabletten mit hoher Festigkeit auf Basis von Herstellung und Verwendung von feinteiligen Vinyllactampolymerenn, deren Herstellung und Verwendung
JP4809194B2 (ja) * 2006-11-15 2011-11-09 株式会社日本触媒 ビニルピロリドン系重合体粉末の製造方法
WO2010052088A1 (de) * 2008-11-04 2010-05-14 Basf Se Verwendung von verbundfolien als verpackungsmaterial für und verfahren zur verpackung von oxidationsempfindlichen polymeren sowie verpackungsformen diese enthaltend
DE202009000692U1 (de) 2008-11-04 2009-04-16 Basf Se Verpackungsform
WO2010072640A1 (de) * 2008-12-22 2010-07-01 Basf Se Verfahren zur stabilisierung von polymeren
EP3777864A1 (en) 2010-11-04 2021-02-17 Albireo AB Ibat inhibitors for the treatment of liver diseases
US8623978B2 (en) 2010-11-23 2014-01-07 Basf Se Process for the preparation of low-peroxide crosslinked vinyllactam polymer
DE202011005055U1 (de) 2011-04-12 2011-09-12 Basf Se Peroxidarmes Polymer enthaltend Phosphorverbindung
US9023931B2 (en) 2011-04-12 2015-05-05 Basf Se Oxidation-sensitive, low-peroxide polymer comprising at least one inorganic phosphorus compound
EP2511331A1 (de) 2011-04-12 2012-10-17 Basf Se Peroxidarmes Polymer enthaltend Phosphorverbindung
DE112012001679B4 (de) 2011-04-12 2023-05-04 Basf Se Abgeschlossene, schutzgasgefüllte Verpackungsform, enthaltend ein oxidationsempfindliches, peroxidarmes Polymer, dessen Verwendung und Verfahren zur Stabilisierung von oxidationsempfindlichen Polymeren gegen Peroxidbildung
US9260546B2 (en) 2012-08-08 2016-02-16 Basf Se Producing aqueous solutions of vinyllactam polymers and powders thereof
WO2014023602A1 (de) 2012-08-08 2014-02-13 Basf Se Verfahren zur herstellung wässriger lösungen von vinyllactam-polymeren und deren pulver
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
CN108685164B (zh) * 2018-03-21 2021-01-29 云南中烟工业有限责任公司 降低烟气中co释放量的亚铁配合物添加剂及其制备方法与应用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
IL279464B2 (en) 2018-06-20 2025-12-01 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) * 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) * 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
BR112021005253A2 (pt) * 2018-09-19 2021-06-15 Isp Investments Llc composição de polímero estável a peróxido e processo para sua preparação e aplicações da mesma
CA3106374A1 (en) 2019-01-11 2020-07-16 Encapsys, Llc Incorporation of chitosan in microcapsule wall
CN119490657A (zh) * 2023-08-21 2025-02-21 万华化学集团股份有限公司 一种颜色稳定、黄度降低的聚砜的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2439196C3 (de) * 1974-08-16 1978-11-02 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von Polyvinylpyrrolidon
DE3532747A1 (de) * 1985-09-13 1987-03-26 Basf Ag Verfahren zur herstellung von polyvinylpyrrolidon
CA2075481C (en) * 1990-02-27 2006-03-28 Peter Gyulai Hydrogen peroxide destroying compositions and methods of making and using same
US5364601A (en) 1992-12-30 1994-11-15 Bausch & Lomb Incorporated Treating of contact lenses with compositions comprising PVP-H202
DE19640365A1 (de) * 1996-09-30 1998-04-02 Basf Ag Polymer-Wasserstoffperoxid-Komplexe

Also Published As

Publication number Publication date
PT1083884E (pt) 2003-02-28
EP1083884A1 (de) 2001-03-21
ATE226066T1 (de) 2002-11-15
DK1083884T3 (da) 2002-11-04
DE19915420A1 (de) 2000-10-12
JP2002541091A (ja) 2002-12-03
EP1083884B1 (de) 2002-10-16
WO2000059478A1 (de) 2000-10-12
DE50000639D1 (de) 2002-11-21
CN1174743C (zh) 2004-11-10
CN1313760A (zh) 2001-09-19
US6592900B1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
ES2185584T3 (es) Procedimiento para estabilizar preparaciones de polivinilpirrolidona.
WO2002080976A3 (en) Hsa-free formulations of interferon-beta
AU2002305099A1 (en) Fatty alcohol drug conjugates
HRP950337A2 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
AU2002316811A1 (en) Stable formulation of modified glp-1
AU7207098A (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
TNSN07290A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
AU2002366042A1 (en) Solid dispersions containing substituted cyclodextrin and insoluble drug and their preparations
MY142354A (en) Acidic insulin preparations having improved stability
MXPA05002814A (es) Formulacion para agentes lipofilicos.
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
AU2001295017A1 (en) Solid dose nanoparticulate compositions
AU2002346296A1 (en) Block copolymer reduced in impurity content, polymeric carrier, pharmaceutical preparations in polymeric form and process for the preparation of the same
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
EP1145719A3 (en) Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
UA88300C2 (ru) Гидрогелевые композиции, которые содержат интерферон
IL155297A0 (en) Kahalalide f formulation
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
AU2003269792A1 (en) Pharmaceutical formulation of olanzapine
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
AU1556000A (en) Composition allowing predefined and controlled release of active ingredient, preparation thereof and use